UNSPSC 51341503: Foscarnet

This classification denotes a reverse transcriptase inhibitor with the molecular formula CH3O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 364P9RVW4X, chemically known as phosphinecarboxylic acid, dihydroxy-, oxide but generally known as foscarnet, which bears US NIH Compound Identifier 3415. European Medicines Agency schedules Foscarnet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02258MIG.

World Health Organization schedules foscarnet in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, FOSCARNET remains the US FDA Preferred Term for this commodity. Foscarnet bears US NLM identifiers UMLS ID C0070895 and NCI Concept Code C71630. SMILES: P(=O)(O)(O)C(=O)O.

UNSPSC 51341503 Foscarnet, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The code nominally covers foscarnet sodium, an antiviral pharmaceutical, yet the four recent opportunities on file solicit naloxone and drug deactivation systems, therapeutic pharmacy initiatives, generic multi-source pharmaceuticals and OTC products, and medical and first aid supplies — none of which are foscarnet-specific products. The mismatch suggests either systematic miscoding in the source system or that foscarnet procurement activity does not currently surface in state and local competitive solicitations. The issuing bodies represented span state health agencies, county health departments, city purchasing offices, and cooperative purchasing alliances: Seminole County, Florida; Texas Health and Human Services Commission; City of Tampa; and the Minnesota Multistate Cooperative Purchasing Alliance (administered by the Minnesota Department of Administration). The scope of work across these opportunities centers on pharmaceutical supply, medical consumables, and pharmacy benefit management, but none directly target foscarnet products.

The recent activity geographically concentrates in Florida, Texas, and Minnesota, with the Texas RFI and Minnesota MMCAP solicitation operating as state-level or multi-state mechanisms. Representative opportunities include Seminole County's IFB 60459723LAS (due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries; the City of Tampa's Bid 26-P-00145 (due March 13, 2026) for medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000 and designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount; Texas HHS Commission's RFI HHS0017013 (due April 3, 2026) exploring direct-to-manufacturer pharmacy benefit capabilities; and MMCAP's RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local facilities. The code shows little relevant recent activity targeting foscarnet specifically and should be monitored for corrected coding or emerging demand signals.